Navigation Links
GATA: a graphic alignment tool for comparative sequence analysis

Sometimes a potential target for a drug seems very promising on paper; things are often very different in reality. Its the case of telomerase inhibitors to treat cancer; they are supposed to strip the "immortal" (able to divide indefinitely) aspect of cancer cells. Yet, something in the cell seems to block their function, preventing them to inhibit completely the telomerase. What to do then? Scrap the project? Look for something else? Hell no! Look out for whats stopping the drug! Perseverance is sometimes worth it, as we can see. A new research study published in the January issue of Cancer Cell provides exciting new information about how to boost the effectiveness of a promising cancer treatment that targets telomeres in an attempt to interfere with the ability of a cancer cell to continuously divide.

Telomeres are DNA sequences found at the ends of chromosomes that play a key role in controlling the life span of cells. With every cell division, telomeres get a bit shorter until eventually they become so short that the enzymes that copy DNA for cell division no longer work properly and the cell stops dividing. In a sense, telomeres function as a kind of counting mechanism that regulates how many times a cell can divide. In contrast to normal cells, cancer cells divide continuously and uncontrollably. Scientists know that cancer cells produce an enzyme, called telomerase, which prevents telomeres from getting too short so cells can keep dividing. Telomerase is not used by healthy cells, and has been identified as a logical target for anticancer therapeutics. However, recent studies indicate that for this therapy to be effective, telomeres must be in a critically short state, requiring an extended treatment duration that can lead to drug resistance and other problems. Dr. Hiroyuki Seimiya from the Japanese Foundation for Cancer Research in Tokyo and colleagues examined what happens to cancer cells when telomerase inhib ition is combined with inhibition of an enzyme called tankyrase 1 that is involved in making telomeres accessible to telomerase. The researchers found that both tankyrase 1 activity and telomere shortening decrease the effects of telomerase inhibitors. Importantly, tankyrase inhibition enhanced telomere shortening upon treatment with a telomerase inhibitor and accelerated cancer cell death. "This study provides insight into strategies for telomere-based molecular cancer therapeutics. We expect that inhibition of tankyrase 1 will compensate for incomplete inhibition of telomerase. Consequently, this strategy would shorten the time period of drug treatment that is required for the onset of telomere crisis and reduce the potential risk of acquired drug resistance, " writes Dr. Seimiya. Hiroyuki Seimiya, Yukiko Muramatsu, Tomokazu Ohishi, and Takashi Tsuruo: "Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics".
'"/>

Source:


Related biology news :

1. International Team Determines Geographic Origin of Leprosy
2. Past droughts geographically widespread in the West, according to tree-ring data
3. Use of stone hammers sheds light on geographic patterns of chimpanzee tool use
4. Preliminary study finds holographic imaging system promising for cancer treatment planning
5. New comparative toxicogenomics database
6. Viral DNA sequence a possible trigger for breast cancer
7. Found: Missing sequence of the human Y chromosome
8. Researchers uncover sequence of major rice pathogen
9. Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays
10. Oldest fossil human protein ever sequenced
11. Deep thinking: Scientists sequence a cold-loving marine microbe

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/14/2019)... ... January 14, 2019 , ... CellMax Life , a ... blood, will present new findings at the ASCO Gastrointestinal Cancer Symposium in San ... results from this study show CellMax Life’s blood test, based on its proprietary ...
(Date:1/10/2019)... ... January 10, 2019 , ... ... translational gap between inexpensive in vitro studies and significantly more expensive in vivo ... vivo efficacy and toxicity. To address this need, researchers have begun to adopt ...
(Date:1/7/2019)... (PRWEB) , ... January 07, 2019 , ... ... (RWD) and Artificial Intelligence solutions for precision health in oncology and other key ... J.P Morgan’s exclusive meeting of investors, entrepreneurs and executives spanning the entire healthcare ...
Breaking Biology News(10 mins):
(Date:1/20/2019)... ... January 16, 2019 , ... On January 15 of this year, ... by Asymmetrex director James L. Sherley, M.D., Ph.D. The PGCB was ... the PGCB and CellTrials.org. Now in its 21st year of operation, the PGCB ...
(Date:1/20/2019)... LOUISVILLE, Ky. (PRWEB) , ... January 17, 2019 ... ... and an Autodesk Platinum Partner announces the launch of a specialized automation technology, ... customer requested parameters for automatic generation of models and drawings to deliver to ...
(Date:1/15/2019)... ... January 15, 2019 , ... With the U.S. Congress designating January as Cervical ... (STD) testing service, today announces tips to help reduce the risk of Cervical Cancer. , ... (HPV). Genital HPV is the #1 most common STD and an STI that ...
(Date:1/10/2019)... ... 2019 , ... Rascal was adopted from a local shelter when he was around two years ... Unfortunately, just six weeks after he was adopted, he tore his right cruciate ligament. ... the joint after such a traumatic injury. , Sure enough, when Rascal was about nine ...
Breaking Biology Technology: